10 vs 5 years of adjuvant tamoxifen: exclusion of 1/402 centres in ATLAS

Lancet. 2017 May 13;389(10082):1884. doi: 10.1016/S0140-6736(17)31003-6. Epub 2017 Apr 28.

Authors

Christina Davies¹, Hongchao Pan², Richard Peto²

Affiliations

¹ ATLAS International Co-ordinating Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK. Electronic address: [email protected].
² ATLAS International Co-ordinating Centre, Nuffield Department of Population Health, University of Oxford, Oxford, UK.

PMID: 28457628
DOI: 10.1016/S0140-6736(17)31003-6

No abstract available

Publication types

Letter
Comment

MeSH terms

Antineoplastic Agents, Hormonal
Breast Neoplasms*
Chemotherapy, Adjuvant
Humans
Receptors, Estrogen
Tamoxifen*

Substances

Antineoplastic Agents, Hormonal
Receptors, Estrogen
Tamoxifen

Grants and funding